ESMO26: Bayer’s Phase III Nubeqa win leaves survival and abiraterone questions open
With these results, Nubeqa enters a setting where other androgen-directed therapies have produced mixed results.
Comment & Opinion
ESMO26: GSK’s Mo-Rez seeks an edge in a crowded ADC field in ovarian cancer
ESMO26: Oral cell cycle inhibitors place Cyclin E1 as new target in PROC
Egypt reforms obsolete pharmaceutical pricing framework
Danish fast-track model inspires growth in national reimbursement rates
Global systems unprepared for rising threat of invasive fungal infections
CPHI 2026: Finding the right CDMO partner in an age of consolidation
Suspected plague outbreak in Russia: public health risk lower than Covid-19
